Amphastar Pharmaceuticals (AMPH) Income towards Parent Company (2013 - 2026)

Amphastar Pharmaceuticals has reported Income towards Parent Company for 14 years, with the latest figure at $30.3 million in Q2 2026.

• On a quarterly basis, Income towards Parent Company fell 2.2% year-over-year to $30.3 million in Q2 2026; TTM through Jun 2026 was $83.4 million, a 32.15% decrease from a year earlier, with the FY2025 full-year figure at $103.0 million, down 30.58% from the prior year.
• Income towards Parent Company was $30.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $6.4 million in the prior quarter.
• The five-year high for Income towards Parent Company was $49.6 million in Q3 2023, with the low at $6.4 million in Q1 2026.
• Average Income towards Parent Company over 5 years is $28.5 million, with a median of $28.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Income towards Parent Company jumped 530.36% in 2022, then sank 74.61% in 2026.
• Over 5 years, Income towards Parent Company stood at $29.3 million in 2022, then increased by 14.09% to $33.4 million in 2023, then slipped by 21.4% to $26.2 million in 2024, then gained by 11.78% to $29.3 million in 2025, then advanced by 3.48% to $30.3 million in 2026.
• The last three Income towards Parent Company figures came in at $30.3 million (Q2 2026), $6.4 million (Q1 2026), and $29.3 million (Q4 2025), per Business Quant data.